The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial

Hum Reprod. 2010 Sep;25(9):2264-9. doi: 10.1093/humrep/deq188. Epub 2010 Jul 27.


Background: Submucous fibroids are common benign tumours responsible for menorrhagia, subfertility and miscarriage. They can be readily removed by hysteroscopic transcervical resection of myoma (TCRM). To facilitate resection, pre-operative GnRH analogues have been suggested, but the value of this treatment is uncertain. Our aim was to assess the value of pre-operative GnRH analogues for the resection of submucous fibroids.

Methods: This was a prospective, double-blind, placebo-controlled, randomized trial. Women found to have submucous fibroids on three-dimensional saline infusion sonohysterography (3D SIS) were randomized to receive GnRH or placebo. Following treatment patients underwent TCRM by a single operator blinded to the group allocation. Women were followed up 6 weeks after their operation to ascertain resolution of symptoms. The primary outcome measure of the study was completeness of fibroid resection. Secondary outcome measures included the duration of the TCRM, the fluid deficit recorded at TCRM, the resolution of symptoms post-operatively and the number of subsequent fibroid related operations.

Results: Forty-seven women were randomized to GnRH or placebo. On the basis of intention-to-treat analysis, there was no significant difference in the number of complete fibroid resections between women who received GnRH analogues [14/24, 58.3% (95% CI 38.6-78.1)] and those who received placebo [16/23, 69.6% (50.8-88.4)] (RR 0.84, 95% CI 0.54-1.29; P = 0.43). Similarly there was no significant difference between the groups in any of the secondary outcome measures.

Conclusions: Our study does not support routine administration of GnRH analogues before transcervical resection of fibroid as we did not identify any benefit in such treatment.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Blood Loss, Surgical
  • Blood Volume / drug effects
  • Body Fluids / drug effects
  • Combined Modality Therapy
  • Double-Blind Method
  • Female
  • Gonadotropin-Releasing Hormone / agonists
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Goserelin / administration & dosage
  • Goserelin / therapeutic use
  • Humans
  • Leiomyoma / drug therapy*
  • Leiomyoma / surgery*
  • Middle Aged
  • Postoperative Complications / epidemiology
  • Premedication*
  • Reoperation
  • Statistics as Topic
  • Time Factors
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / surgery*


  • Antineoplastic Agents, Hormonal
  • Goserelin
  • Gonadotropin-Releasing Hormone

Associated data

  • ISRCTN/ISRCTN06560767